UPDATE: Citi Lowers PT on Hospira to $43

Citi is out with its report today on Hospira HSP, lowering its PT to $43 from $51. In its report, Citi writes, "Last Friday's announcement of approval for the solution version of Gemzar (gemcitabine) is a plus, but our analysis of this pending launch and 2 others expected in 2H11 still leaves us feeling underwhelmed about the prospects heading into 2012. We are lowering our EPS estimates – including a 2011 forecast below guidance - and our target falls to $43 on significant peer group multiple compression." Citi maintains Sell on HSP. Shares of HSP closed Monday at $44.40, down 6.68% from Friday's close.